AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
August 08, 2022 16:05 ET
|
AnaptysBio, Inc.
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing rosnilimab...
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 05, 2022 16:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
June 02, 2022 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control...
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
May 04, 2022 16:15 ET
|
AnaptysBio, Inc.
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing imsidolimab...
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
April 27, 2022 16:15 ET
|
AnaptysBio, Inc.
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement...
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
March 21, 2022 16:15 ET
|
AnaptysBio, Inc.
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE)...
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
March 14, 2022 16:20 ET
|
AnaptysBio, Inc.
Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpointsAnaptysBio to discontinue imsidolimab clinical development in...
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
March 07, 2022 08:50 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing imsidolimab ACORN Phase 2 trial in...
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
November 29, 2021 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...